2023 Fiscal Year Final Research Report
Development of a Novel Atherosclerosis Treatment Using Nanobubbled ApoA-I Mimetic Peptide and Ultrasound
| Project/Area Number |
18K08090
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
三浦 伸一郎 福岡大学, 医学部, 教授 (20343709)
朔 啓二郎 福岡大学, 医学部, 教授 (40183371)
立花 克郎 福岡大学, 医学部, 教授 (40271605)
|
|---|
| Project Period (FY) |
2018-04-01 – 2024-03-31
|
| Keywords | アポ蛋白A-I模倣ペプチド / ナノバブル / 抗動脈硬化作用 / 抗炎症作用 |
|---|
| Outline of Final Research Achievements |
We investigated methods to enhance the anti-atherosclerotic effects of the apoprotein A-I mimetic peptide FAMP. It was revealed that nanobubbles accumulated in atherosclerotic lesions in the aorta of mouse when FAMP and nanobubbles were applied simultaneously. We demonstrated that FAMP has the effect of suppressing inflammatory cytokines, which can potentially cause atherosclerosis, and that this effect is enhanced when used in combination with nanobubbles. By altering some of the amino acids that make up FAMP, we created a peptide with stronger cholesterol efflux capacity and demonstrated its anti-atherosclerotic effect.
|
| Free Research Field |
動脈硬化
|
| Academic Significance and Societal Importance of the Research Achievements |
心血管疾患は日本人の死因の第2位であり、その原因となる動脈硬化の発症予防、治療が重要である。本研究では、善玉といわれるHDLの機能を増強させる作用をもつアポ蛋白A-I模倣ペプチドFAMPを改良し、その抗動脈硬化作用を高める方法を検証した。本研究で明らかとなったFAMPとナノバブル併用の効果、FAMPの抗炎症作用、改良型FAMPの抗動脈硬化作用から、動脈硬化性疾患の克服に向けた新たな治療薬への開発へ繋がっていくと考えられる。
|
